{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-22-001587","form_type":"8-K","ticker":"ALDX","cik":"0001341235","company_name":"Aldeyra Therapeutics, Inc.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.274127+00:00","generated_at":"2026-06-21T22:31:56.246817+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aldeyra Q3 net loss $14.6M; reproxalap NDA on track for Q4 2022; cash $185M","bullets":["Net loss of $14.6M ($0.25 per share) for Q3 2022 vs $15.8M ($0.27) for Q3 2021.","Cash, cash equivalents, and marketable securities of $185.3M as of Sep 30, 2022; expected to fund operations through end of 2023.","NDA submission for reproxalap in dry eye disease remains on schedule for Q4 2022; package includes data from five adequate and well-controlled trials.","Pre-NDA meeting with FDA scheduled in Q4 2022 to discuss ADX-2191 for primary vitreoretinal lymphoma; NDA possible by end of 2022.","Top-line results from Phase 2 trial of ADX-629 in acute alcoholic hepatitis expected by end of 2022; ADX-2191 retinitis pigmentosa trial results expected H1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-22-001587","json":"https://secwatch.observer/filing/0001157523-22-001587.json","markdown":"https://secwatch.observer/filing/0001157523-22-001587.md","text":"https://secwatch.observer/filing/0001157523-22-001587.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1341235/000115752322001587/0001157523-22-001587-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1341235/000115752322001587/a52965769.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T22:31:56.246817+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bacf5e2a98a4947f592a96d44cee6eb3ba6dddfd","claim":"Aldeyra Therapeutics, Inc. reported the quarter ended September 30, 2022 results: net income Net loss for the three months ended September 30, 2022 was $14.6 million, EPS $0.25 per share.","evidence_excerpt":"Net loss for the three months ended September 30, 2022 was $14.6 million, or $0.25 per share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1341235/000115752322001587/0001157523-22-001587-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Net income","value":"Net loss for the three months ended September 30, 2022 was $14.6 million"},{"label":"EPS","value":"$0.25 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}